Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
07 April 2000Website:
http://www.lexpharma.comNext earnings report:
08 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 23:59:29 GMTDividend
Analysts recommendations
Institutional Ownership
LXRX Latest News
THE WOODLANDS, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the outcome of the U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting to review the company's New Drug Application (NDA) for Zynquista (sotagliflozin), an oral SGLT1/SGLT2 inhibitor, as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes (T1D) and chronic kidney disease (CKD). The Advisory Committee voted 11 to 3 that the benefits of Zynquista do not outweigh the risks in adults with T1D and CKD, as defined in the voting question as having estimated glomerular filtration rate (eGFR) > 45 to 60 mL/min/1.73 m2 and urine albumin-to-creatinine ratio (uACR) > 30mg/g.
Independent advisers to the U.S. Food and Drug Administration on Thursday voted against recommending Lexicon Pharmaceuticals' add-on treatment to insulin therapy for managing blood glucose levels in adults with type 1 diabetes and chronic kidney disease.
THE WOODLANDS, Texas, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeff Wade, president and chief operating officer, has decided to step down to pursue new opportunities outside of Lexicon, effective September 30, 2024. A search for a new chief financial officer is ongoing.
Study results aligned with positive clinical trial outcomes for type 1 diabetes treatment with sotagliflozin
The FDA plans to hold an Advisory Committee meeting to give a recommendation for Lexicon's (LXRX) Zynquista (sotagliflozin) on Oct 31, 2024. Stock up.
Lexicon (LXRX) announces a portfolio reprioritization plan to focus on reducing operational expenses and driving the growth of the commercial portfolio. Shares rise.
Company to Focus on Targeted Promotion of INPEFA® in Heart Failure While Prioritizing Investment in the Potential Launch of ZYNQUISTA™
THE WOODLANDS, Texas, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that three poster presentations will be delivered during the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists being held August 9 - 12, 2024 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.
Lexicon Pharmaceuticals' launch of Inpefa continues to progress very slowly; prescriptions grew nearly 50% QoQ, but revenue is still below $2M and missing sell-side expectations. New leadership and cash reserves provide opportunities for Lexicon to improve commercial execution and drive revenue growth, and improved patient access and payer coverage are 2H'24 priorities. The company has resubmitted its application for Zynquista in Type 1 diabetes, a commercially significant opportunity, but one where regulatory and execution risk are still very present.
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ) Q2 2024 Earnings Conference Call August 1, 2024 5:00 PM ET Company Participants Lisa DeFrancesco – Head-Investor Relations and Corporate Strategy Mike Exton – Chief Executive Officer and Director Jeff Wade – President and Chief Financial Officer Tom Garner – Senior Vice President and Chief Commercial Officer Craig Granowitz – Senior Vice President and Chief Medical Officer Alan Main – Executive Vice President, Innovation and Chemical Sciences Conference Call Participants Yasmeen Rahimi – Piper Sandler Andrew Tsai – Jefferies Joe Pantginis – H.C. Wainwright Roanna Ruiz – Leerink Partners Operator Good day and welcome to Lexicon Pharmaceuticals Second Quarter 2024 Financial Results Conference Call.
- 1(current)
- 2
What type of business is Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
What sector is Lexicon Pharmaceuticals in?
Lexicon Pharmaceuticals is in the Healthcare sector
What industry is Lexicon Pharmaceuticals in?
Lexicon Pharmaceuticals is in the Biotechnology industry
What country is Lexicon Pharmaceuticals from?
Lexicon Pharmaceuticals is headquartered in United States
When did Lexicon Pharmaceuticals go public?
Lexicon Pharmaceuticals initial public offering (IPO) was on 07 April 2000
What is Lexicon Pharmaceuticals website?
https://www.lexpharma.com
Is Lexicon Pharmaceuticals in the S&P 500?
No, Lexicon Pharmaceuticals is not included in the S&P 500 index
Is Lexicon Pharmaceuticals in the NASDAQ 100?
No, Lexicon Pharmaceuticals is not included in the NASDAQ 100 index
Is Lexicon Pharmaceuticals in the Dow Jones?
No, Lexicon Pharmaceuticals is not included in the Dow Jones index
When was Lexicon Pharmaceuticals the previous earnings report?
No data
When does Lexicon Pharmaceuticals earnings report?
The next expected earnings date for Lexicon Pharmaceuticals is 08 November 2024